AICF's 2020-21 Fellow:
Paolo D'Amico, MD
Use of liquid biopsy methods to predict endocrine sensitivity in HR+ metastatic breast cancer
"I am a medical oncology resident with a strong interest in translational research and molecular medicine. My clinical training was spent evaluating the safety of patients receiving early-phase drugs and the management of related toxicities.
In order to increase the number of patients eligible to target-therapy, I’m currently focusing my efforts on the identification of new predictive biomarkers in the blood of metastatic breast cancer patients. The project aim is to identify a new cohort of patients that can benefit from these promising drugs, improving survival and patients’ quality of life."